Nima Nabavizadeh, M.D. is an assistant professor in the Department of Radiation Medicine. Dr. Nabavizadeh maintains both clinical and translational research activities while also seeing patients as a Radiation Oncologist. In medical school, Dr. Nabavizadeh was awarded the Doris Duke Charitable Foundation Clinical Research Fellowship at the University of California, San Francisco and Lawrence Berkeley National Laboratory. After medical school, Dr. Nabavizadeh trained in Radiation Oncology at OHSU. His past research activities have spanned murine model experiments, retrospective studies and cross-departmental prospective studies. His ongoing work is funded by the Radiological Society of North American, American Society of Clinical Oncology and Radiation Oncology Institute. Learn about Dr. Nabavizadeh's ROI research.
The Nabavizadeh group studies cross-complimentary approaches to cancer treatment, identifying methods to improve quality of life, reduce toxicity, and increase progression free survival. Our cross-collaborative group partners with other researchers within the department, the Spellman Lab at OHSU, and researchers at other institutions. Current projects range from translational projects involving human subjects, prospective clinical trials, population studies, and meta-analyses.
Predicting neoadjuvant treatment response using circulating tumor DNA in peripheral blood Treatment effectiveness analyses for non-surgical management of hepatocellular carcinoma Assessment of microvascular response to high-dose radiation therapy using contrast-enhanced ultrasound Adherence and reasons for non-adherence to a tri-modality regimen in the treatment of esophageal cancer
John Minger, Senior Research Associate
Ramtin Rahmani, Research Associate
March 9, 2020
Nima Nabavizadeh, M.D. was interviewed by OHSU's Cancer Translated blog for his research on using radiation to boost circulating DNA for ‘liquid biopsy’ of cancer.
May 2, 2019
Nima Nabavizadeh, M.D. shared his perspective on Skipping Surgery for Rectal Cancer with Medpage Today.
May 10, 2019
Nima Nabavizadeh, MD was awarded a Radiation Oncology Institute 2018 Innovative Projects in Radiation Oncology award. Dr. Nabavizadeh will be investigating expanding the use of SBRT to bridge hepatocellular carcinoma patients with advanced cirrhosis to the liver transplant they need to survive. Learn more: https://bit.ly/2wvfa9T.
May 9, 2016
Nima Nabavizadeh, M.D. has been selected to attend the FLIMS17 Methods in Clinical Cancer Research workshop in Flims, Switzerland. This program is sponsored by the ECCO, AACR, EORTC, & ESMO. This intensive workshop is to help emerging clinical oncologists to learn the essentials of clinical trial design & execution. The course takes place from June 20-26, 2015 at the Chalet Belmont Hotel in the confines of the Waldhaus Flims Mountain Resort & Spa.
May 20, 2015
Nima Nabavizadeh, M.D. received a $500 cash prize for earning 1st place in the annual department of diagnostic radiology research retreat held in April 2015. Dr. Nabavizadeh's research is sponsored, in part, by a 2014 RSNA Research Resident/Fellow grant.
Thermal Ablation Versus Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score Weighted Analysis. Nabavizadeh N, Jahangiri Y, Rahmani R, Tomozawa Y, Geeratikun Y, Chen Y, Hung A, Degnin C, Farsad K. American Journal of Roentgenology. doi.org/10.2214/AJR.20.24117
Flushing, Vomiting, and Abdominal Pain Following Abdominal Ultrasonography. Rahmani R, Raess PW, Nabavizadeh N. JAMA Oncol. 2020 Jul 30. doi: 10.1001/jamaoncol.2020.0787.
ACR-ASTRO Practice Parameter for Image-guided Radiation Therapy (IGRT). Luh JY, Albuquerque KV, Cheng C, Ermoian RP, Nabavizadeh N, Parsai H, Roeske RC, Weiss SE, Wynn RB, Yu Y, Rosenthal SA, Hartford A. Am J Clin Oncol. 2020;43(7):459-468. doi:10.1097/COC.0000000000000697
Correction to: Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent? Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt CK, Maynard E, Ahn J, Lhewa D, Farsad K.Cardiovasc Intervent Radiol. 2020 Sep;43(9):1425-1426. doi: 10.1007/s00270-020-02554-x.
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma [published online ahead of print, 2020 Jul 19]. Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR. CA Cancer J Clin. 2020;10.3322/caac.21626. doi:10.3322/caac.21626
ACR–ASTRO Practice Parameter for Image-guided Radiation Therapy (IGRT). Luh JY, Albuquerque KV, Cheng C, Ermoian RP, Nabavizadeh, Parsai H, Roeske, JC, Weiss SE, Wynn RB, Yu Y, Rosenthal SA, Hartford A. American Journal of Clinical Oncology: 22 May 2020. doi: 10.1097/COC.0000000000000697
Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent? Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Cardiovasc Intervent Radiol. 2020 Mar 5. doi: 10.1007/s00270-020-02434-4
Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise. Mitin T, Degnin C, Chen Y, Shirvani S, Gillespie E, Hoffe S, Latifi K, Nabavizadeh N, Dengina N, Chernich M, Usychkin S, Kharitonova E, Egorova Y, Pankratov A, Tsimafeyeu I, Thomas CR Jr, Tjulandin S, Likhacheva A. J Cancer Educ. 2020 Feb;35(1):105-111. doi: 10.1007/s13187-018-1447-0.
Contrast-Enhanced Ultrasound to Detect Early Microvascular Changes in Skeletal Muscle after High-Dose Radiation Treatment. Nabavizadeh N, Qi Y, Kaempf A, Chen Y, Tanyi JA, Lindner JR, Wu MD. Radiat Res. 2020 Feb;193(2):155-160. doi: 10.1667/RR15471.1
Evolving Treatment Options and Future Directions for Locally Advanced Rectal Cancer. Chen EY, Kardosh A, Nabavizadeh N, Lopez CD. Clin Colorectal Cancer. 2019 Dec;18(4):231-237. doi: 10.1016/j.clcc.2019.06.005.
Stop hedging your bets: reasons for non-adherence to a tri-modality regimen in the treatment of esophageal cancer in a multidisciplinary setting. Rahmani R, Koffler D, Haisley KR, Hunter JG, Poliakoff C, Thomas CR Jr, Holland JM, Dolan JP, Nabavizadeh N. J Gastrointest Oncol. 2019 Jun;10(3):387-390. doi: 10.21037/jgo.2019.01.24.
Low-Dose Radiation Therapy is an Effective Treatment for Refractory Postoperative Chylous Ascites: A Case Report. Brown S, Abana CO, Hammad H, Brown A, Mhlanga J, Binder C, Nabavizadeh N, Thomas C Jr, Mitin T, Gilbert EW. Pract Radiat Oncol. 2019 May;9(3):153-157. doi: 10.1016/j.prro.2018.12.001.
Use of the g-index for assessment of citation-based scholarly activity of United States radiation oncology residents and subsequent choice of academic versus private practice career. McClelland Iii S, Mitin T, Nabavizadeh N, Fuller CD, Thomas CR Jr, Jaboin JJ. Rep Pract Oncol Radiother. 2019 May-Jun;24(3):294-297. doi: 10.1016/j.rpor.2019.03.005.
Prophylactic Aortic Stent Prevents Massive Hemorrhage and Hematemesis After Definitive Esophageal Chemoradiation in a Patient With Pretreatment Aortic Involvement. Murphy B, Azarbal A, Schenning RC, Bensch K, Sukumar M, Stelzer K, Nabavizadeh N. Pract Radiat Oncol. 2019 Sep - Oct;9(5):e447-e451. doi: 10.1016/j.prro.2019.05.008.